Trials / Active Not Recruiting
Active Not RecruitingNCT06295692
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
A Phase 3, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77242113 | JNJ-77242113 tablet will be administered orally. |
Timeline
- Start date
- 2024-02-09
- Primary completion
- 2025-01-14
- Completion
- 2027-10-14
- First posted
- 2024-03-06
- Last updated
- 2026-04-13
- Results posted
- 2026-01-28
Locations
12 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06295692. Inclusion in this directory is not an endorsement.